Compare AAON & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAON | RYTM |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | 1995 | 2017 |
| Metric | AAON | RYTM |
|---|---|---|
| Price | $80.65 | $115.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | $117.50 | ★ $140.12 |
| AVG Volume (30 Days) | 1.5M | ★ 1.5M |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 2.06 | N/A |
| Revenue | ★ $1,442,076,000.00 | N/A |
| Revenue This Year | $74.10 | $73.80 |
| Revenue Next Year | $16.48 | $73.86 |
| P/E Ratio | $38.29 | ★ N/A |
| Revenue Growth | ★ 20.11 | N/A |
| 52 Week Low | $53.13 | $74.50 |
| 52 Week High | $150.46 | $122.20 |
| Indicator | AAON | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 65.94 |
| Support Level | $75.32 | $82.31 |
| Resistance Level | $89.67 | $119.75 |
| Average True Range (ATR) | 6.02 | 6.84 |
| MACD | 1.92 | 2.19 |
| Stochastic Oscillator | 82.29 | 94.00 |
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which derives maximum revenue, engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.